Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cathay Biotech Inc. (688065.SS)
CNY43.25
+0.32 (+0.75%)
CN SHH Basic Materials Chemicals
Address
Building #5 201203
Shanghai, CN
Shanghai, CN
CEO
Xiucai Liu
Website
cathaybiotech.com
IPO
2020-08-12
ISIN CNE100004447
Description
Cathay Biotech Inc. specializes in biochemical products, producing and marketing bio-based polyamide, bio-based DN5, long chain dibasic acids, and biobutanol. The company's corporate base is located in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY43.25
+0.32 (+0.75%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.47
Float Shares
259.14M
Free Float %
35.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.05% | -3.76% | -4.06% | -13.76% | -9.11% | -5.98% | -7.58% | -13.30% | -16.33% | -58.25% | -58.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
43.25
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.60
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Chemicals: +4.0%+11.4% ★ Q1'26: +12.7% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-1.2% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-1.1% Q1'26: -36.2% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+19.2% ★ Q1'26: +22.1% (vs Q1'25)
-
ROIC Chemicals: +3.4%+4.5% ★ Q1'26: +5.0% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+17.1% Q1'26: +21.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.53× ★ Q1'26: 1.41× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.50B
est: 1.97B (-23.8%)
|
2.36B
est: 2.35B (+0.5%)
|
2.44B
est: 3.12B (-21.7%)
|
2.11B
est: 2.12B (-0.4%)
|
2.96B
est: 2.96B (+0.1%)
|
3.30B
est: 3.07B (+7.3%)
|
3.57B
3.57B – 3.57B
+16.2% YoY
|
4.05B
4.05B – 4.05B
+13.6% YoY
|
4.51B
4.51B – 4.51B
+11.3% YoY
|
| EBITDA |
643.28M
est: 542.11M (+18.7%)
|
909.28M
est: 648.64M (+40.2%)
|
985.74M
est: 859.77M (+14.7%)
|
772.51M
est: 585.55M (+31.9%)
|
897.41M
est: 1.03B (-13.0%)
|
947.42M
est: 1.07B (-11.6%)
|
1.25B
1.25B – 1.25B
+16.2% YoY
|
1.41B
1.41B – 1.41B
+13.6% YoY
|
1.57B
1.57B – 1.57B
+11.3% YoY
|
| EBIT |
524.96M
est: 345.16M (+52.1%)
|
740.74M
est: 412.99M (+79.4%)
|
720.62M
est: 547.42M (+31.6%)
|
486.80M
est: 372.82M (+30.6%)
|
581.49M
est: 725.45M (-19.8%)
|
631.50M
est: 753.43M (-16.2%)
|
875.65M
875.65M – 875.65M
+16.2% YoY
|
994.43M
994.43M – 994.43M
+13.6% YoY
|
1.11B
1.11B – 1.11B
+11.3% YoY
|
| Net Income |
457.67M
est: 482.31M (-5.1%)
|
594.72M
est: 638.92M (-6.9%)
|
553.27M
est: 753.82M (-26.6%)
|
366.52M
est: 367.04M (-0.1%)
|
488.96M
est: 552.09M (-11.4%)
|
565.72M
est: 620.25M (-8.8%)
|
780.42M
780.42M – 780.42M
+25.8% YoY
|
872.44M
872.44M – 872.44M
+11.8% YoY
|
961.04M
961.04M – 961.04M
+10.2% YoY
|
| SGA |
143.25M
est: 174.90M (-18.1%)
|
175.11M
est: 209.26M (-16.3%)
|
232.28M
est: 277.38M (-16.3%)
|
221.61M
est: 188.91M (+17.3%)
|
222.00M
est: 206.40M (+7.6%)
|
—
est: 214.36M (-100.0%)
|
249.13M
249.13M – 249.13M
+16.2% YoY
|
282.93M
282.93M – 282.93M
+13.6% YoY
|
314.84M
314.84M – 314.84M
+11.3% YoY
|
| EPS |
0.84
est: 0.83 (+1.4%)
|
1.02
est: 1.10 (-7.1%)
|
0.95
est: 1.30 (-26.6%)
|
0.63
est: 0.63 (+0.8%)
|
0.84
est: 0.81 (+3.7%)
|
0.83
est: 0.91 (-8.8%)
|
1.15
1.15 – 1.15
+25.8% YoY
|
1.28
1.28 – 1.28
+11.8% YoY
|
1.41
1.41 – 1.41
+10.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
757.96M
OE per share TTM
1.21
Owner's Yield
2.24%
Maintenance CapEx ratio
50.69%
Maint CapEx / Avg PPE
214.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 36 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares ICBCUBS SSE Star Market 50 Index UCITS ETF KSTR.L | 0.50% | 338.1K | 0.82% |
| 2 | KraneShares SSE STAR Market 50 Index ETF KSTR | 0.50% | 1.91M | 0.89% |
| 3 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.15% | 56.6K | 0.65% |
| 4 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.06% | 9.5K | 0.65% |
| 5 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.04% | 27.4K | 0.55% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 30.8K | 0.19% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 134.0K | 0.19% |
| 8 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 3.1K | 0.15% |
| 9 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 83.5K | 0.46% |
| 10 | Amundi Prime Emerging Markets UCITS ETF DR (C) PRAM.L | 0.00% | 60.3K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
364.0K
Shares Outstanding
721.29M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Benliang Hou | Vice President | — | male |
| Chen Yang | Vice President, Core Technician & Chief Operating Officer | — | male |
| Hong Guang Zhang | Vice President | — | male |
| Huiqing Zang | Vice President, Secretary of the Board of Directors & Director | — | female |
| Jun Zuo | Vice President | — | male |
| Xiao Kun Chen | Accounting Supervisor | — | — |
| Xiucai Liu | Chairman & President | — | — |
| Yijun Du | Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688065.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
